September 12, 2026 — localized fat removal scope expansion
Expanded the category to regional subcutaneous fat and visceral-fat reduction, including notable formal human programs, new indications and GLP-1 combinations. Removed the CBL-514 identification/confirmation narrative. Updated the cover page, active watchlist, same-day initial brief, detailed topic and existing automation prompt.
| Coverage | Baseline added or clarified | Next trigger |
|---|---|---|
| CBL-514 | Retreatment studies, secondary lipoma/cellulite indications, and caution about the upcoming human/preclinical VAT presentation | September 30 EASD presentation; September CBL-514D sponsor window; registry estimates in 2027–2028 |
| RZL-012 | September 2 China Phase 3 sponsor topline, earlier U.S. trial safety, and early flank evidence | Full results; China filing targeted by end-2026; body-contouring trial registration |
| AYP-101 | Published Phase 2 and completed Phase 3, with no posted Phase 3 results | Results/publication; no dependable release date |
| Tesamorelin | Approved HIV-related use; selected non-HIV VAT evidence; posted non-HIV fatty-liver results; unverified follow-on commercial trial launch | Full publication, endpoint clarification, funded new trials/indications; no dependable date |
| Established comparators | Kybella and Korea-approved MT921/NUVIJU | Major formal new indication, body-site or regulatory developments |
Primary sources and numerical findings are linked in the updated topic. These additions are starting evidence for the expanded scope, not all newly released news. Posted registry results for RZL-012 and tesamorelin were inspected, and AYP-101's completed/no-results status was checked through the primary registry API.
Limits and next checks: reconcile the older SUPREME-01 registry with newer sponsor announcements; obtain the EASD abstract before interpreting VAT findings; obtain full RZL-012 Phase 3 data; watch AYP-101 results; clarify tesamorelin's liver-fat change units and seek peer-reviewed results. The tesamorelin record titled “Mock Study” is excluded from real trial milestones.
The other eight categories were not rescanned in this scoped update. Their successful-check timestamps are preserved. Existing baseline event records remain intact; newly reviewed programs and sources are added for deduplication. The recurring task remains active Tuesday/Friday at 9 a.m. Eastern and retains meaningful-change-only notifications.